• Antimycin A4: ATP-Citrate Lyase Inhibitor for Metabolic Stud

  2026-05-21

  Antimycin A4 offers unparalleled precision for dissecting ATP-citrate lyase and mitochondrial function, enabling advanced metabolic and cytotoxicity research. This article delivers actionable protocols, troubleshooting strategies, and translational insights for researchers seeking robust, reproducible results.

• Bone Transport Enhances DFU Healing via TGF-β1 Pathway Coupl

  2026-05-20

  This study demonstrates that bone transport accelerates diabetic foot ulcer (DFU) healing by activating TGF-β1-mediated angiogenic and osteo-immune coupling. The findings establish a mechanistic link between bone-driven signaling and reparative processes in chronic wound repair, highlighting the TGF-β1/TGFBR1 axis as a promising therapeutic target.

• Busulfan in Germ Cell Depletion: Mechanistic Nuance & Assay

  2026-05-20

  Explore Busulfan’s unique mechanism as a DNA alkylating agent for precision germ cell depletion and senescence models. This article reveals advanced insights into MAPK pathway activation, experimental design, and the latest genetic tracing findings to guide your research.

• Topotecan and Etoposide: Mechanistic Insights in DNA Damage

  2026-05-19

  The referenced review details the pharmacological innovation and clinical deployment of topotecan, a topoisomerase I inhibitor, in oncology. It highlights the mechanistic contrasts with topoisomerase II inhibitors like etoposide, informing experimental choices in DNA damage and apoptosis research.

• Technical Use of Angiotensin I/II (1-5) in RAS Research

  2026-05-19

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for precise modeling of blood pressure regulation and aldosterone stimulation within the renin-angiotensin system. It is specifically suited for cardiovascular and renal workflows, and should not be used in unrelated signaling studies due to its limited solubility and defined mechanism.

• AR and ARv7 Drive Metastasis in TNBC: EPI-001 as a Targeted

  2026-05-18

  This study reveals that androgen receptor (AR) and its splice variant ARv7 are associated with poor prognosis and increased metastasis in triple-negative breast cancer (TNBC). Targeting AR/ARv7 using the N-terminal domain inhibitor EPI-001 disrupts metastatic and EMT pathways, highlighting a mechanistically distinct approach for AR-driven TNBC.

• EdU Imaging Kits (488): Precision S-Phase Profiling in Neuro

  2026-05-18

  Explore how EdU Imaging Kits (488) and 5-ethynyl-2'-deoxyuridine enable next-level S-phase DNA synthesis measurement for advanced cell proliferation assays. This article uniquely bridges high-sensitivity click chemistry detection with insights from neuromodulatory anti-proliferative technologies.

• Dihydroartemisinin: Applied Protocols and mTOR Pathway Insig

  2026-05-17

  Dihydroartemisinin—a high-purity Artemisia plant extract—enables advanced research into malaria, inflammation, and cell signaling with robust mTOR pathway inhibition. This article delivers actionable workflows, protocol enhancements, and troubleshooting tips, translating recent reference breakthroughs into practical laboratory strategies.

• Prednisone in Research: Deep Mechanistic Insights and Assay

  2026-05-16

  Explore the mechanistic depth of Prednisone, a synthetic corticosteroid, in immunology and neurodegeneration research. This article uniquely integrates molecular mechanisms, assay design considerations, and advanced metabolomics findings to guide cutting-edge experimental strategies.

• AR and ARv7 as Prognostic Drivers in TNBC: Evidence from EPI

  2026-05-15

  This study delineates the prognostic significance of androgen receptor (AR) and its splice variant ARv7 in triple-negative breast cancer (TNBC), linking their expression to worse survival and increased metastasis. It further demonstrates that targeting AR/ARv7 with N-terminal domain inhibitors like EPI-001 modulates key metastatic and EMT pathways in TNBC models, offering mechanistic insight into new intervention strategies.

• Dihydrotestosterone (DHT): Mechanistic Evidence & Research U

  2026-05-15

  Dihydrotestosterone (DHT) is a potent endogenous androgen and agonist of the androgen receptor. It upregulates EGFR and ERBB2 signaling in AR-positive cancer models and confers functional and molecular benefits in ALS mouse models. APExBIO’s DHT B8214 provides a rigorously characterized tool for dissecting androgen receptor pathways in translational research.

• Optogenetic RNA-Releasing Protein Enables Light-Controlled G

  2026-05-14

  A recent study introduces a rationally designed light-inducible RNA-releasing protein (LIRP) that acts as a gene switch, enabling precise, light-dependent translational regulation in mammalian cells. This innovation offers a platform for on-demand gene therapies, with particular potential in treating chronic metabolic and retinal diseases requiring controlled transgene activity.

• Pomalidomide (CC-4047): Precision Tools for Myeloma Research

  2026-05-14

  Pomalidomide (CC-4047) enables high-fidelity immunomodulation and tumor microenvironment studies in hematological malignancy research. This guide delivers actionable workflow enhancements, troubleshooting expertise, and data-driven insights to maximize reproducibility and impact in advanced multiple myeloma models.

• MAPK10 Suppresses NSCLC Metastasis via KRT16 Phosphorylation

  2026-05-13

  This study identifies mitogen-activated protein kinase 10 (MAPK10) as a suppressor of non-small cell lung cancer (NSCLC) metastasis. Through phosphorylation-dependent ubiquitination of keratin 16 (KRT16), MAPK10 promotes proteasomal degradation of KRT16, revealing a potential axis for therapeutic targeting and prognostic biomarker development in NSCLC.

• EPZ5676: Applied DOT1L Inhibition for Precision Epigenetic A

  2026-05-13

  EPZ5676, a potent and highly selective DOT1L inhibitor, is transforming workflows in leukemia and fibrosis research. This article translates recent breakthroughs and expert protocols into actionable steps, enabling scientists to maximize the value of EPZ5676 in both cancer epigenetics and kidney fibrosis models.

445 records 17/30 page Previous Next First page 上5页 1617181920 下5页 Last page